Wyniki wyszukiwania

1

Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik

Tularemia – serious zoonotic disease

100%

Weiner M., Kubajka M.

Health Problems of Civilization

|

2015

|

tom 09

|

nr 1

Tularemia is an acute, infectious zoonotic disease caused by a smal. aerobic, intracellular, gram-negative bacillus Francisella tularensis. Tularemia was firstly described towards the end of nineteenth century in Japan, however, the name Francisella comes from Edward Francis, an American researcher who in 1911 detected this bacterium in squirrels in Tulare County, California. In Poland tularemia in humans was recognized for the first time in 1949. In the years 1949 to 2009, over 600 tularemia cases were recorded in Poland, with one fatality in 1983. Initial work on the use of F. tularensis as a biological weapon was carried out in the 30s of the twentieth century simultaneously in the United States, Soviet Union and Japan. The natural reservoirs of the micro-organism are rodents and lagomorphs, which can be a source of infection for other animals and humans. Human infection occurs through direct contact with sick animal. inhalation of dust contaminated with feces of sick animals and it takes place mainly in the farms involved in the animal production, to a lesser extent as a result of contaminated food and water.

2

First report of molecular identification of Cystoisospora suis in piglets with lethal diarrhea in Japan

84%

Matsubayashi M., Takayama H., Kusumoto M., Murata M., Uchiyama Y., Kaji M., Sasai K., Yamaguchi R., Shibahara T.

Acta Parasitologica

|

2016

|

tom 61

|

nr 2

3

New challenges in trichinellosis control

84%

Dupouy-Camet J.

Wiadomości Parazytologiczne

|

2006

|

tom 52

|

nr 3

4

Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis

67%

Chojnacki C., Wisniewska-Jarosinska M., Walecka-Kapica E., Klupinska G., Jaworek J., Chojnacki J.

Journal of Physiology and Pharmacology

|

2011

|

tom 62

|

nr 3

Ulcerative colitis (UC) is a chronic disease characterized by the variable clinical picture with the inflammatory changes which can involve the whole colon or its distal part. The current treatments for UC are mostly nonspecific, not always effective, and often accompanied by serious side effects. Therefore, there is a considerable interest in finding alternative and more tolerable treatments for this serious disease. Several lines of experimental studies have shown that melatonin (MEL) regulates the extensive gut immune system and exerts antiinflammatory and immunomodulatory effects suggesting its beneficial action in UC by reducing and controlling inflammation. The study aimed at evaluating the effect of MEL on the activity of inflammatory process and sustaining the remission in patients with UC. It comprised 60 patients with left-sided UC, divided in two equal groups of 30 patients each (38 women and 22 men, aged 26-49 years), similar in both groups, who were in clinical remission for the last 12 months. Patients, during a next period of 12 months, were given mesalazine in daily doses 2 x 1.0 g and melatonin 5 mg daily at bedtime (group I) or placebo (group II). All the patients on MEL adjuvant treatment remained in remission during 12 months of observation with The Mayo Clinic Disease Activity Index (MCDAI) values 1.50±0.51 at the beginning and 2.75±1.86 points after 12 months. In the placebo group significantly higher MCDAI values were observed than in patients on MEL after 6, 9 and 12 months. At the inclusion MCDAI was 1.61±0.68 points and at the end of observation it reached the value of 5.10±2.22 points. In MEL group CRP level remained within the normal range during the course of the study (from 3.49±1.40 to 4.17±2.10 mg/dl). Whereas in the placebo group from the end of the third month the steady rise in CRP blood concentration was noted from 3.85±1.29 to 13.13±6.08 mg/dl. Parallelly to CRP rise a significant decrease in hemoglobin concentration in blood from 12.05±0.69 to 10.93±0.81 g/dl was observed in patients receiving placebo and the values significantly differed between the groups after 3 (p<0.05), 6, 9 and 12 months (p<0.01). The level of anxiety and the intensity of depression in patients on adjuvant MEL decreased during the study but there were no statistical differences noted between the groups. The results of the study allowed drawing the conclusion that adjuvant melatonin therapy may help in sustaining remission in patients with UC.

5

Diagnostics in pulmonary hypertension

67%

Schannewll C. M., Steiner S., Strauer B.-E.

Journal of Physiology and Pharmacology. Supplement

|

2007

|

tom 58

|

nr 5

6

Clinical, haematological and biochemical studies in goats naturally infected with Mycoplasma agalactiae

67%

Kizil O., Ozdemir H.

Bulletin of the Veterinary Institute in Puławy

|

2006

|

tom 50

|

nr 3

Ograniczanie wyników

Tularemia – serious zoonotic disease

First report of molecular identification of Cystoisospora suis in piglets with lethal diarrhea in Japan

New challenges in trichinellosis control

Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis

Diagnostics in pulmonary hypertension

Clinical, haematological and biochemical studies in goats naturally infected with Mycoplasma agalactiae